Fig. 1From: Cost-effectiveness of pembrolizumab versus chemotherapy in patients with platinum-pretreated, recurrent or metastatic nasopharyngeal cancerModel structure for Platinum-pretreated, Recurrent or Metastatic NPC. NPC, Nasopharyngeal carcinoma; P, Partitioned survival model; PFS, progression-free survival; PD, progressed diseaseBack to article page